Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

View all news

Latest News

View all news

Latest Financial Results

Q2 2025

Quarter Ended Dec 31, 2024
Earnings Release
PDF HTML
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2024

Report Links

2022 Proxy Statement

Leadership

View Management Team View Board of Directors

IR Contacts

Company

Anebulo Pharmaceuticals, Inc.
1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
T: 512-598-0931
ir@anebulo.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
8th Floor
New York, NY 10004

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.